Download data is not yet available.


The development of immune cell-based approaches for treatment of cancer has been actively investigated for many years. One strategy that has been demonstrated as an effective method for cancer treatment is adoptive T cell therapy. The principle of this method is using Cytotoxic T lymphocytes (CTL), a crucial component of the adaptive immune system that aids in the control of intracellular pathogens. Effector CTL have the capacity to promote the apoptotic death of specifically targeted cells, using a combination of granule (perforin/granzyme)-and receptor (Fas/tumor necrosis factor)-mediated mechanisms. CTL recognize specific antigen on target cells using an unique T-cell receptor (TCR) when they are presented by class I major histocompatibility (MHC) molecules. In this study, we demonstrated that T lymphocytes were activated and dramatically expanded by stimulation with anti-CD3/CD28 antibodies and culture in the present of IL-2, IL-15 and IL-21 cytokines. These T cells exhibited a predominantly activated phenotype as manifested by an increase in the percentage of cells expressing CD8 and generation of various cytokines such as IL-2, INFγ and TNFa. These findings indicate that stimulation by anti- CD3/CD28 generated effector CTL in adoptive T-cell therapy for cancer.

Author's Affiliation

 Copyright Info

Creative Commons License

Copyright: The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 How to Cite
Ta, V., Tran, T., Nguyen, B., Nguyen, L., Nguyen, H., & Tran, K. (2017). ID:4007 Immune-cell base for cancer therapy. Biomedical Research and Therapy, 4(S), S10.

 Cited by

Article level Metrics by Paperbuzz/Impactstory
Article level Metrics by Altmetrics

 Article Statistics
HTML = 185 times
Download PDF   = 28 times
Total   = 28 times